Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TC-N201 in Advanced Solid Tumors
NCT05881525Phase 1Recruiting
- Sponsor
- TCRCure Biotech
- Start
- Jun 2023
- Primary completion
- Nov 2027
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TC-N201 in solid tumor, sponsored by TCRCure Biotech. Primary endpoints: Dose Limiting Toxicity or Maximum Tolerated Dose (MTD) at Day 28, Overall response rate and 1 more. Started Jun 2023; status: recruiting.
02
Drugs
TC-N201
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05881525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05881525.